This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2017
  • /
  • 09
  • /
  • Merck Inc. to acquire Rigontec GmbH and with it RG...
Industry news

Merck Inc. to acquire Rigontec GmbH and with it RGT 100 which is currently in Phase I/II in advanced solid tumors .

Read time: 1 mins
Last updated:9th Sep 2017
Published:9th Sep 2017
Source: Pharmawand
Merck Inc. and Rigontec GmbH announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec�s lead candidate, RGT 100, is currently in Phase I development evaluating treatment in patients with various tumors. Under the terms of the agreement, Merck, through a subsidiary, will make an upfront cash payment of �115 million to Rigontec�s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, Merck may make additional contingent payments of up to �349 million. The transaction is subject to certain closing conditions.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights